Wednesday, march 19, a step forward for access to medical cannabis in France
"
Medical cannabis: government moves towards widespread use in France
By the end of 2023, French parliamentarians had passed measures that would enable the marketing of cannabis-based treatments. However, these provisions never came into force, as they require the Ministry of Health to officially notify the European Commission - which was done on Wednesday.
The authorization of cannabis-based treatments in France, which has been for over a year, has taken a major step forward with the government's announcement, on Wednesday March 19, of a crucial administrative formality.
The texts defining the framework for the production and authorization of cannabis for medical use have been notified to the European Commission, reported the Ministry of Health in a press release. It also clarified the situation of patients treated under the current experimental which will be extended “exceptionally” until March 31, 2026. In theory, this postponement will make it possible to project the experiment into the future. “This is a new stage in the development of supervised, secure access to medical cannabis in France”, stressed the Ministry. The experiment for patients undergoing treatment was initially due to end in 2024. They had already been granted until summer 2025.
Ludovic Rachou, President of the Union des industriels pour la valorisation des extraits de chanvre (Union of industrialists for the valorization of hemp extracts), hailed “a relief for patients who no longer have to think about withdrawal” and “a reason for hope for future patients”. “We would warmly thank the Minister for his support, and remain mobilized to ensure the creation of a pharmaceutical industry, with all the players involved from the outset”, he added in a press release.
France lags behind
The medical use of cannabis to treat pain and anxiety has been the subject of experimentation in France for several years. Many countries already offer such treatments. Judging that this experiment had been successful at the end of 2023, members of parliament voted for measures to enable the marketing of cannabis-based treatments. Initially, these would be subject to a five-year transitional. However, these provisions never came into force, as they required the Ministry of Health to officially notify the European Commission.
This has not yet been done, and some experts involved in the experiment, explained this blockage by the governmental instability observed over the period or a lack of political will. Wednesday's announcement by the Ministry unblocks the situation. Depending on discussions with the EU, experts estimate that it will take at least six months after this notification to consider the concrete arrival of treatments.
In addition, as the Ministry reminded us on Wednesday, any reimbursement of these treatments will depend on an assessment by the French health authority. However, there is no consensus on the benefits of medical cannabis. The main benchmark study, published in 2021 in the British Medical Journal (BMJ) and based on numerous other studies, concluded that medical cannabis offers “limited” or “very limited” improvement in patient outcomes."
Source : Cannabis médical, le gouvernement avance vers une généralisation en France,
AFP Le Monde, 03/20/2025